PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function

Phase 2 Unknown 36 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Yichang Humanwell Pharmaceutical Co., Ltd., China · collab

RandomizedParallel-groupSingle-blindOther

Summary

Pharmacokinetic/pharmacodynamic profiles of remazolam besylate were compared in patients with impaired and normal renal function in the ICU, and safety was assessed by recording hemodynamic parameters and adverse events.

Timeline

Start: 2023-11-04
Primary completion: 2024-12
Completion: 2024-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remimazolam	Small molecule	0.2 mg/kg	—

Indications

No indication recorded.